The effect of bromocriptine in benign prostatic hypertrophy and vesicosphincteric dynamics.
Four studies were carried out on 66 patients in order to examine the effect of bromocriptine in benign prostatic hypertrophy (BPH) and to clarify its mechanism of action. Two studies were clinical: the first was a double-blind, controlled trial (lasting 6 months) in which bromocriptine 5 mg/day was compared with placebo, and the second was an open study to evaluate the effect of bromocriptine 5 mg on patients with acute retention due to BPH. The other two studies were designed to investigate the action of the drug on vesicosphincteric dynamics. These were double-blind, controlled, parallel trials, one comparing bromocriptine at dosages of 2.5 and 5 mg with placebo 90 min after administration, and the other comparing bromocriptine 5 mg/day with placebo after 15 days' administration in post-prostatectomy patients. Bromocriptine had a favourable effect on patients with BPH but no effect on cases of acute retention. The urodynamic studies suggested that the drug affected urethral sphincteric mechanisms specifically. The weight and volume of the prostate remained unchanged after administration of the drug, so that any clinical response was not due to a direct effect on the gland itself.
D001971:Bromocriptine / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D011467:Prostate / Q000187:drug effects; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D011897:Random Allocation; D014521:Urethra / Q000187:drug effects* / Q000503:physiopathology; D001743:Urinary Bladder / Q000187:drug effects* / Q000503:physiopathology; D014554:Urination / Q000187:drug effects
D001971:Bromocriptine